Antibodies are secreted immunoglobulin molecules produced mainly by plasma cells. The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly ...

We are following a blueprint, and our participation in South Africa is part of our roadmap to the World Cup," said the ZNA President. When asked about the administrative issues surrounding NSA ...

Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases. The funding consists of a $30 million series ...

The goals of this report are to present the global data accrued for bedinvetmab, the first monoclonal antibody for canine osteoarthritis, and to explore reporting patterns globally and across major ...

2025年4月23日，在第10个中国航天日来临前夕，山东省滨州市博兴县第一小学开展“学习航天知识 探索宇宙奥秘”活动，组织小学生在老师带领下来到博兴县科技馆，通过现场讲解、参观展品、互动体验等方式，让小学生零距离学习航天知识，感受航天科技魅力 ...

SAN FRANCISCO--(BUSINESS WIRE)--Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer ...

Veraxa, founded on scientific discoveries at the European lab, said it’s recently widened its scope to focus on two hot areas in cancer research: antibody-drug conjugates and T cell engagers. Veraxa ...

Full results from the trial evaluating Akeso’s first-in-class PD-1/VEGF bispecific antibody are expected to be presented later this year at a medical conference. 1 "The interim analysis results from ...

The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and other medications. AI-based computational models are expected to play a larger role ...

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc.

Molecular parameters governing antibody FcγR signaling and effector functions in the context of HIV envelope. Cell Reports , 2025; 44 (4): 115331 DOI: 10.1016/j.celrep.2025.115331 Cite This Page : ...